Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
783
datasets available to search
ShareScore release 0.7.1
Dataset results
783 results for “lung adenocarcinoma”
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
ClinicalTrials.gov study NCT04527419. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
ClinicalTrials.gov study NCT04459078. IPD Sharing: YES. Countries: 1. Publications: 1.
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
ClinicalTrials.gov study NCT01565538. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
ClinicalTrials.gov study NCT00284141. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Multi-omics with dynamic network biomarker algorithm prefigures organ-specific metastasis of lung adenocarcinoma
<p><span>Efficacious strategies for early detection of lung cancer metastasis are of significance for improving the survival of lung cancer patients. Utilizing two clinical cohorts of four major types of lung cancer distant metastases, with single-cell RNA sequencing (scRNA-seq) of primary lesions and liquid chromatography mass spectrometry data of sera, we identified the marker genes and serum secretome foreshadowing the lung cancer site-specific metastasis through dynamic network biomarker (DNB)</span> <span>algorithm. Also, we located the intermediate status of cancer cells, along with its gene signatures, in each metastatic state trajectory that cancer cells at this stage still had no specific organotropism. Furthermore, an integrated neural network model based on the filtered scRNA-seq data was successfully constructed and validated to predict the metastatic state trajectory of cancer cells. Overall, our study provided a new insight to locate the pre-metastasis status of lung cancer and primarily examined its clinical application value, contributing to the early detection of lung cancer metastasis in a more feasible and efficacious way.</span></p>
Preliminary Report on Computed Tomography Radiomics Features as biomarkers to Immunotherapy selection in Lung Adenocarcinoma Patients
<p>We uploaded all radiomics metrics extracted for 88 patients enrolled in the study: Preliminary Report on Computed Tomography Radiomics Features as biomarkers to Immunotherapy selection in Lung Adenocarcinoma Patients.</p> <p>Each radiomic feature is described in the Appendix of the manuscript.</p> <p>Moreover Overall survival (OS) and Progression free survival (PFS) for each patient is provided.</p>
Spatiotemporal Profiling Unveiling the Cellular Organization Patterns and Local Protumoral Immune Microenvironment Remodeling in Early Lung Adenocarcinoma Progression
<p>Spatial cellular organization patterns (COPs) in tumor microenvironment influence the tumor progression and therapeutic response, however, little is known about the cellular composition and functional potential of these multicellular structures during lung adenocarcinoma progression. Here, we integrate spatial transcriptomics with single cell RNA sequencing to characterize the local tumor and immunological landscape of samples from 8 patients with lung adenocarcinoma at different pathological stages. We identified ten COPs that show distinct associations with local immune states and clinical outcomes, including survival and therapy response. The local infiltration levels of regulatory and dysfunctional immune cells are increased with pathological progression. Cell-to-cell interactions between malignant cells and tumor microenvironment (TME) cells were involved in protumor immune state remodeling. Finally, we detected a group of malignant cells that were specifically located at the tumor boundary, representing a more aggressive state, were involved in the invasion of invasive adenocarcinoma (IAC). Altogether, these results can improve our understanding of the local microenvironment characteristics that underlie LUAD progression and may facilitate the identification of drug targets to prevent invasive progression and biomarkers for diagnosis.</p><p>If you're going to use this dataset, please cite 'Haojie Chen et al. 2023. Protumoral Immune Microenvironment Remodeling in Early Lung Adenocarcinoma Progression. bioRxiv. https://doi.org/10.1101/2023.10.29.564580'</p>
Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma
ClinicalTrials.gov study NCT03904563. IPD Sharing: NO. Countries: 1. Publications: 13.
Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype
ClinicalTrials.gov study NCT01774526. IPD Sharing: Not stated. Countries: 1. Publications: 14.
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
ClinicalTrials.gov study NCT04588064. IPD Sharing: NO. Countries: 1. Publications: 1.
Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma
ClinicalTrials.gov study NCT02281708. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
ClinicalTrials.gov study NCT06181812. IPD Sharing: Not stated. Countries: 1. Publications: 9.
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung
ClinicalTrials.gov study NCT00816868. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
ClinicalTrials.gov study NCT02303977. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene
ClinicalTrials.gov study NCT03905317. IPD Sharing: NO. Countries: 1. Publications: 19.
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
ClinicalTrials.gov study NCT01051934. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma
ClinicalTrials.gov study NCT03709147. IPD Sharing: NO. Countries: 1. Publications: 16.
Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma
ClinicalTrials.gov study NCT03380468. IPD Sharing: UNDECIDED. Countries: 1. Publications: 21.
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
ClinicalTrials.gov study NCT06528847. IPD Sharing: NO. Countries: 1. Publications: 3.
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
ClinicalTrials.gov study NCT05689671. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.